[18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: Experience in 100 consecutive patients

Marino Cimitan, Roberto Bortolus, Sandro Morassut, Vincenzo Canzonieri, Antonio Garbeglio, Tanja Baresic, Eugenio Borsatti, Annalisa Drigo, Mauro G. Trovò

Research output: Contribution to journalArticlepeer-review

Abstract

Purpose: We evaluated the potential of PET/CT and [18F] fluoromethylcholine (FCH) in the assessment of suspected recurrence of prostate cancer after treatment. Methods: One hundred consecutive prostate cancer patients with a persistent increase in serum PSA (>0.1 ng/ml) after radical prostatectomy (58 cases), radiotherapy (21 cases) or hormonal therapy alone (21 cases) were investigated. After injection of 3.7-4.07 MBq/kg of FCH, both early (at 60 min) PET/CT scans were performed in 43 patients, delayed PET/CT scans in 53 patients and early PET/CT scans in four patients. Results: Of the 100 patients, 54 (PSA 0.22-511.79 ng/ml) showed positive FCH PET/CT scans. Thirty-seven patients had bone and/or abdominal lymph node uptake, while 17 showed pelvic activity. Malignant disease was confirmed in all but one. Delayed SUVmax of bone metastases was significantly higher (p

Original languageEnglish
Pages (from-to)1387-1398
Number of pages12
JournalEuropean Journal of Nuclear Medicine and Molecular Imaging
Volume33
Issue number12
DOIs
Publication statusPublished - Dec 2006

Keywords

  • Choline
  • PET
  • Prostate cancer

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology

Fingerprint Dive into the research topics of '[18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: Experience in 100 consecutive patients'. Together they form a unique fingerprint.

Cite this